SOX2 and glioblastoma: Patient-derived GBM organoids stand out by retaining diverse tumor cell subtypes from patients, indicated by GSC markers Sox2, CD133, Nestin and more differentiated progenies expressing Tuj1 or DCX [15, 17, 19].